Women Get a ‘Lift’ With New Breast Procedure
Each year in the U.S., more than 350,000 women go under the knife to get breast implants and while statistics show the majority of women are satisfied with the results, there are a number of women who are left feeling disappointed. Lynn Free Breast Implants Website on WJZ-13 Baltimore
After you’ve responded to the breast enhancing effects of the Breast Actives program you’re sure to turn some heads when you walk into the room.
Some women have tried dangerous, unnatural procedures and treatments to enhance their breasts-often not getting the results they wanted and exposing themselves to potentially dangerous consequences.
The good news is that the Breast Actives program is a…
SEE OTHER SPECIALS AT OUR WEBSITE – www.bountifulbreast.com….
BountifulBreastTM comes with a money-back guarantee (see below). It is used by both males/females and hollywood actresses, [see Jaycee Jules testimonial from the soap opera (Days of our Lives)on our website] BountifulBreast has been marketed for 10 years, has no harmful side-effects, 100% safe, is FDA allowed, no herbs/or estrogenic …
This digital document is an article from Women’s Health Activist, published by Thomson Gale on May 1, 2005. The length of the article is 461 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle: G-spot s…
Dystonia – Drug Pipeline Analysis and Market Forecasts to 2016
The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecasts for seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with dystonia, competitive assessment, product profiles of the major marketed products and promising drugs in the pipeline, implications for future market competition and the key players of the dystonia market. ( http://www.bharatbook.com/detail.asp?id=132248&rt=Dystonia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html )
The Dystonia Market is Forecast to Show High Growth Until 2016 The global dystonia market was worth $536m in 2009. The market is expected to grow by 19.4% during the next seven years to reach $1.9 billion by 2016. Although the drug pipeline for the treatment of dystonia is weak, the launch of Ipsen’s Dysport in early 2009, which is another breakthrough for dystonia sufferers, is the primary driver for increased market growth. The market remains well-served with more than four products, most of which are significantly efficacious in their respective target areas. Essentially, the global dystonia market is heading towards a phase of continuous growth, leveraging the current opportunities.
Competition in Dystonia Market is Strong It found the current competition in the dystonia market to be strong. Allergan’s Botox continues to lead the market followed by Solstice’s Myobloc and Ipsen’s Dysport, accounting for about 80% of global dystonia sales. While the market remains well served by current the botulinum toxins, the newer candidates will have substantial scope for growth and profitability. Botulinum toxins are the most widely preferred and accepted choice of treatment for dystonia than the other drug classes such as anticholinergics and dopaminergics etc. Dysport, another neurotoxin, entered the market in April 2009. This was the only launch that the market has witnessed in the last seven years. Competition among the botulinum toxins is already fierce and may become more intense as more players enter the market, leading to a market share war.
Current Treatment Options Considerably Suffice the Market Demand It found that although there is a narrow range of treatments, they still meet the current market requirements efficiently. Since the dystonia market is dominated by biologics, price has also been an area of concern. Biologics being premium priced have undoubtedly drawn a clear line and gained control over the dystonia market as the gold-standard therapy for dystonia. With the advent of Dysport and the other forms of botulinum toxins that are anticipated, the expectations from these therapies have increased. The lack of a cure will remain an unmet need in the market in the years to come.
Ignorance and Misdiagnosis Hinder Treatment Even after the arrival of promising therapies for dystonia, it still remains a little unknown and often misdiagnosed condition. The cause of the disease is not known and there is no cure. The treatment options available are invasive, temporary and symptomatic. Due to the poor understanding of the disease, there are very few options directed towards the treatment of the disorder. The available treatments have been successful in treating the symptoms efficiently in both mild and severe forms of dystonia. There are two major concerns with the currently available dystonia treatments – safety and pricing. Since there are limited options for the treatment of dystonia, pipeline drugs with better efficacy, affordability, better patient compliance and safety profile are likely to achieve blockbuster status.
Weak Pipeline Incapable of Satisfying Unmet Need in the Near Future This pipeline analysis revealed that there are seven candidates in the various stages of clinical development. Phase II has six pipeline molecules. There is only one molecule in Phase I, PurTox from Mentor, which is expected to be a promising candidate for dystonia. The pipeline molecules differ from each other in terms of mechanism of action. Ironically, the majority of the candidates which are under investigation have received prior approval for other indications. Since most of the research activities are being carried out the recognized universities, the pharmaceutical and biotechnology players are paying less attention towards the development of the molecules for dystonia. There are very few commercialization opportunities for the near future owing to a weak pipeline. Newer therapies therefore need to compete with biologics in order to be successful in the dystonia therapeutics market.
Bharat Book Bureau Tel: +91 22 27578668 Fax: +91 22 27579131 Email: info@bharatbook.com Website: www.bharatbook.com Blog: http://bharatbookresearch.blogspot.com Follow us on twitter: http://twitter.com/3bbharatbook
About the Author
We are the leading information aggregator, facilitates and supports the business information needs. With over 115,000 reports, you can get instant access and insights on the studies in yo for market research , corporate / strategic planning by providing the latest information in the form of reports, journals, magazines and databases on varied industries like automotive, oil and gas, shipping, textiles, pharmaceuticals, energy, banking, finance, insurance, risk management, country intelligence, consumer & durable goods, chemical and more ur areas of interest. Contact us at +91 22 27578668 / 27579438 or email info@bharatbook.com or our website www.bharatbook.com
Botox Sales Could Top $1Botox sales could produce up to …
If you have been wearing spectacles or contact lenses for a long time, and dream of clear vision, then Lasik Surgery could well be your answer. Today an increasing number of people with poor eyesight are turning to this surgery to correct their vision.
What is LASIK?
LASIK is an acronym for Laser-Assisted In Situ Keratomileusis. The goal of the surgery is to alter shape of the cornea, which is the transparent covering on the eye. The process involves the use of a cool “excimer” laser. An instrument called a microkeratome is used to create a flap on the front surface of the cornea to reveal the stroma. This mid-section of the cornea is the portion of the eye which is reshaped with the excimer laser. This cool laser painlessly fixes the nearsightedness, farsightedness and astigmatism that causes poor vision.
The potential risks involved
As part of a LASIK evaluation by your surgeon, you will learn about the risks of surgery. Severe risks that can damage your vision are very rare. By far, the most common problem is under- or over-correction, both of which are almost always correctable with more surgery.
Is it right for you?
Not every patient is a candidate for this procedure. A complete eye exam should be performed by your LASIK surgeon to ensure that you are a candidate for surgery. If you are not a candidate for LASIK, then alternatives such as the Implantable Contact Lens may be discussed. Patients who cannot have LASIK would be people with thin corneas, dry eyes, or other eye diseases.
Just as importantly, patients need to discuss their goals for surgery, and have a clear understanding of the risks and benefits of surgery. These questions MUST be answered by your LASIK surgeon before you proceed with surgery.
Personalized care in a high tech environment…Trust the doctor that doctors trust!
Go to www.2020vision.com now to arrange a free LASIK evaluation with Dr. GoldsteinInformation regarding LASIK eye surgery in Michigan is available at Dr. William Goldstein’s website – www.2020vision.com
